Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Regulation of the intestinal stem cell compartment after hematopoietic transplantation

Award Number: R01HL125571
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2015
PERIOD OF PERFORMANCE END DATE: 05/31/2029

Group Awards By:

View Award Description

Regulation of the intestinal stem cell compartment after hematopoietic transplantation - Intestinal injury is a major complication of allogeneic hematopoietic transplantation, limiting its wider use. The immune system plays a pivotal role in causing intestinal pathology in graft vs. host disease (GVHD) occurring post-transplant, but the immune system can also provide critical contributions to epithelial regeneration and in- testinal repair. We have found that immune-mediated interactions with the intestinal stem cell (ISC) compartment are important contributors to both the damage and regeneration occurring in the intestines in acute GVHD, and the previous funding period resulted in several impactful contributions to understanding immunologic effects on the ISC compartment after bone marrow transplantation (BMT), including that 1) the crypt base ISC compartment is the initial site of donor T cell infiltration within the intestines, where their overproduction of Interferon-g (IFNg) can directly induce Bax/Bak-dependent ISC apoptosis at high concentrations; and 2) Interleukin-(IL-)22 can di- rectly signal to ISCs, promoting their survival and regeneration after damage, and it can be administered thera- peutically post-BMT to promote thymic and intestinal recovery. IL-22 administration can also counteract toxicity from corticosteroids, which reduce ISC proliferation and epithelial regeneration. The experimental work from this project resulted in a multicenter clinical trial treating newly diagnosed gastrointestinal acute GVHD with recom- binant human IL-22. In this renewal, we propose to build upon this progress and conduct a mechanistic evalua- tion of immune-mediated and niche-driven epithelial regeneration in the context of allogeneic BMT. Our new preliminary data indicate profound transcriptomic changes in the ISC compartment in GVHD, identifying a novel pathway of IFNg/STAT1-mediated regulation of ISC c-MYC expression and epithelial regeneration. We believe this pathway induces ISC proliferation at low concentrations of IFNg, whereas high concentrations induce apoptosis. Our new data also indicate that Paneth cell loss may not be driving intestinal pathophysiology in GVHD, and other secretory epithelial cells may also produce growth factors for the niche. Utilizing our experience in ex vivo organoid modeling and ISC immunology, 3-D confocal imaging, and cytokine biology developed in the initial funding period, as well as newly developed approaches for epithelial transcriptomics, we propose to ex- plore these preliminary findings further by 1) investigating the importance of epithelial Myc expression post-BMT using a newly developed model of conditional Myc deletion, 2) dissecting IL-22 and IFNg’s distinct and overlap- ping JAK/STAT responses regulating the ISC compartment, and 3) ablating Paneth cells and other secretory lineage cells to determine their importance for ISC maintenance and epithelial regeneration after transplant. We will then build upon these insights to develop novel approaches manipulating epithelial JAK/STAT signaling and niche function to promote intestinal recovery. This renewal will thus pursue basic mechanisms of transplant biology, mucosal immunology, and stem cell research and extend them to translational investigations with the potential to improve clinical outcomes for transplant patients and others suffering from intestinal pathology.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $766,768 )
2026	2026	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Blood Diseases and Resources Research	000	7	5/1/2026	NON-COMPETING CONTINUATION	$766,768
														Subtotal = $766,768

Issue Date FY: 2025 ( Subtotal = $819,236 )
2025	2025	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Blood Diseases and Resources Research	000	6	9/10/2025	COMPETING CONTINUATION	$819,236
														Subtotal = $819,236

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Blood Diseases and Resources Research	000	5	10/30/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $570,097 )
2019	2019	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Blood Diseases and Resources Research	000	5	4/29/2019	NON-COMPETING CONTINUATION	$570,097
														Subtotal = $570,097

Issue Date FY: 2018 ( Subtotal = $558,680 )
2018	2018	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Blood Diseases and Resources Research	000	4	4/25/2018	NON-COMPETING CONTINUATION	$558,680
														Subtotal = $558,680

Issue Date FY: 2017 ( Subtotal = $558,680 )
2017	2017	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Blood Diseases and Resources Research	000	3	4/7/2017	NON-COMPETING CONTINUATION	$558,680
														Subtotal = $558,680

Issue Date FY: 2016 ( Subtotal = $558,680 )
2016	2016	SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVENUE	NEW YORK	NY	10065	NEW YORK	USA	Blood Diseases and Resources Research	000	2	6/30/2016	NON-COMPETING CONTINUATION	$558,680
														Subtotal = $558,680

Issue Date FY: 2015 ( Subtotal = $558,680 )
2015	2015	SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVENUE	NEW YORK	NY	10065	NEW YORK	USA	Blood Diseases and Resources Research	000	1	6/1/2015	NEW	$558,680
														Subtotal = $558,680

Grand Total All Awards = $4,390,821

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Regulation of the intestinal stem cell compartment after hematopoietic transplantation

Award Number: R01HL125571

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2015

PERIOD OF PERFORMANCE END DATE: 05/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer